Evidence map›Paper›PMID 38195703›Full record

ArticleScientific reports2024

Global analysis of the abundance of AU-rich mRNAs in response to glucocorticoid treatment.

Zeyad Muazzen, Walid Moghrabi, Tala Bakheet, Linah Mahmoud, Maher Al-Saif, Khalid S A Khabar, Edward G Hitti

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zeyad Muazzen *Molecular BioMedicine Department, Research and Innovation, King Faisal Specialist Hospital and Research Centre, 11211, Riyadh, Saudi Arabia.
Walid Moghrabi *Molecular BioMedicine Department, Research and Innovation, King Faisal Specialist Hospital and Research Centre, 11211, Riyadh, Saudi Arabia.
Tala Bakheet *Molecular BioMedicine Department, Research and Innovation, King Faisal Specialist Hospital and Research Centre, 11211, Riyadh, Saudi Arabia.
Linah MahmoudMolecular BioMedicine Department, Research and Innovation, King Faisal Specialist Hospital and Research Centre, 11211, Riyadh, Saudi Arabia.
Maher Al-SaifMolecular BioMedicine Department, Research and Innovation, King Faisal Specialist Hospital and Research Centre, 11211, Riyadh, Saudi Arabia.
Khalid S A KhabarMolecular BioMedicine Department, Research and Innovation, King Faisal Specialist Hospital and Research Centre, 11211, Riyadh, Saudi Arabia.ORCID 0000-0003-1003-9788
Edward G HittiMolecular BioMedicine Department, Research and Innovation, King Faisal Specialist Hospital and Research Centre, 11211, Riyadh, Saudi Arabia. ehitti@kfshrc.edu.sa.
King Faisal Specialist Hospital & Research Centre · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucocorticoids (GC) like dexamethasone (Dex) are potent anti-inflammatory agents with diverse cellular functions including the potentiation of the activity of AU-rich elements (AREs). AREs are cis-acting instability sequence elements located in the 3'UTRs of many inflammatory mediator mRNAs. Here, available RNA-seq data were used to investigate the effect of GCs on the ARE-mRNA-transcriptome. At a global scale, ARE-mRNAs had a tendency to be downregulated after GC-treatment of the A549 lung cancer cell-line, but with notable cases of upregulation. mRNA stability experiments indicated that not only the downregulated, but also the upregulated ARE-mRNAs are destabilized by Dex-treatment. Several of the most upregulated ARE-mRNAs code for anti-inflammatory mediators including the established GC targets DUSP1 and ZFP36; both code for proteins that target ARE-containing mRNAs for destruction. GCs are widely used in the treatment of COVID-19 patients; we show that ARE-mRNAs are more likely to regulate in opposite directions between Dex-treatment and SARS-CoV-2 infections compared to non-ARE mRNAs. The effect of GC treatment on ARE-mRNA abundance was also investigated in blood monocytes of COVID-19 patients. The results were heterogeneous; however, in agreement with in vitro observations, ZFP36 and DUSP1 were often amongst the most differentially expressed mRNAs. The results of this study propose a universal destabilization of ARE-mRNAs by GCs, but a diverse overall outcome in vitro likely due to induced transcription or due to the heterogeneity of COVID-19 patient's responses in vivo.

Indexed as

COVID-19Glucocorticoids3' Untranslated RegionsA549 CellsHumansRNA, Messenger3' Untranslated RegionsGlucocorticoidsRNA, Messenger

Identifiers

PMID38195703
PMCPMC10776588
OpenAlexW4390728192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.